TRIBUNNEWS.COM, LAUSANNE – Medical researcher Swiss said on Wednesday (19/1/2022) that they had launched an early-stage study to test candidates Covid-19 vaccine next generation.
This vaccine candidate will be attached to the arm, and become the newest alternative method of administering the vaccine.
This vaccine candidate is unlike conventional vaccines that stimulate antibody production.
Reported by Channel News Asia, vaccine candidate PepGNP-Covid19 recently focused on T cells, which are responsible for cellular immunity, to eliminate virus-infected cells and prevent them from replicating.
British company Emergex Vaccines Holding Ltd is developing the vaccine candidate.
Also read: Study: Omicron Variant Antibody Can Block Delta Variant Infection
Meanwhile Unisanté’s medical research center in Lausanne in collaboration with the city’s CHUV hospital will run the trial, which begins on January 10.
Lead researcher Professor Blaise Genton said this cellular immunity produces so-called “memory cells”.
These memory cells could make vaccines more durable and could be better than others at fighting viral variants.
Vaccine candidates will be administered through micro-needles on a patch less than one millimeter deep.
PepGNP-Covid19 researchers began vaccinating 26 volunteers last week.
Also read: More Contagious Delta Plus Variant Now Detected in Switzerland
Also read: WHO: No Evidence Healthy Children and Adolescents Need Covid-19 Vaccine Boosters
–
